Efficacy
Consistent results anywhere on the body with foam and cream from head to toe1,2
Study Design
Study Design
ZORYVE cream 0.3% once daily was studied in 881 patients with plaque psoriasis2,5,9:
DERMIS-1 and DERMIS-2
Mild to severe plaque psoriasis (IGA ≥2)
BSA up to 20% (range: 2%-20%, mean: 7%)
77% of patients reported itch with a baseline WI-NRS ≥4
No concomitant therapies or moisturizers/emollients were allowed on treated areas
PRIMARY ENDPOINT
IGA Success at Week 82,9
Achievement of an IGA score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline
KEY SECONDARY ENDPOINTS
WI-NRS Success at Weeks 2, 4, and 82,9
Achievement of a ≥4-point improvement from baseline in patients with baseline score of ≥4
I-IGA Success at Week 82,9
Achievement of an I-IGA score of Clear (0) or Almost Clear (1) and a ≥2-grade improvement from baseline
PASI-75 at Week 89
Achievement of a 75% reduction in PASI score from baseline
Clearance Rates
POWERFUL SKIN CLEARANCE ANYWHERE DISEASE PRESENTS
Primary Endpoint IGA Success
Key Secondary Endpoint I-IGA Success
Almost 6x as many patients achieved
body clearance at Week 8 vs vehicle2,9
Data are pooled analyses of the DERMIS-1 and DERMIS-2 studies.
IGA Success rates at Week 8 were consistent regardless
of baseline BSA involvement (mild, moderate, severe)11
70% of patients achieved intertriginous
area clearance at Week 8 vs vehicle2,9,10
Data are pooled analyses of the DERMIS-1 and DERMIS-2 studies.
ZORYVE is the only branded topical for plaque psoriasis specifically
indicated for use in intertriginous areas2,5
Nearly all patients had IMPROVED CLINICAL SIGNS with ZORYVE
9 out of 10 (95%) had any PASI improvement at Week 8 vs 71% with vehicle5
40% achieved PASI-75 at Week 8 vs 7% with vehicle5,9,12
12% achieved PASI-100 (complete response) at Week 8 vs 1% with vehicle5
Pooled PASI response rates ZORYVE n=576 and vehicle n=305. Analysis provides a summary of PASI improvement for every patient in DERMIS-1 and DERMIS-2. PASI response rates are defined as percentage of patients with improved PASI scores from baseline to Week 8. PASI scores evaluate the following plaque psoriasis symptoms: erythema, skin thickness (induration), and desquamation (scaling).
ITCH RESPONSE
RAPID ITCH RELIEF
WI-NRS Success
~70% of patients experienced itch relief at Week 8 vs vehicle9
Data are pooled analyses of DERMIS-1 and DERMIS-2 studies.
In a global survey, ITCH was the #1 most bothersome symptom reported by patients with psoriasis8‖
‖ A 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) telephone survey of 3426 patients ≥18 years old diagnosed with psoriasis and/or psoriatic arthritis by a healthcare provider. 79% of patients had psoriasis alone.